T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis.

Background: Current guidelines consider T-DM1 the standard 2 line therapy for HER2 positive metastatic breast cancer (MBC) patients following trastuzumab (T) + pertuzumab (P) and taxane 1 line treatment. Despite this, there are no prospective studies supporting this sequence.

Methods: We performed a meta-analysis using real world data to determine the efficacy of T-DM1 after 1 line TP in HER2 positive MBC patients.